# Novo Nordisk

driving unprecedented growth through its GLP-1 peptide therapeutics for diabetes and obesity.

Source: https://en.bioecon.ru/companies/novo-nordisk/
Updated: 2026-06-24

- Country: Denmark
- Ticker: NVO

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | The company funds its capital expenditure and operations through cash flow from operating activities | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm |
| Capacity | Novo Nordisk is the world's largest manufacturer of insulin and GLP-1, and is currently undergoing significant capacity expansions globally including API, aseptic, and fill-finish production to meet high demand | https://www.globenewswire.com/news-release/2023/11/10/2778052/0/en/Novo-Nordisk-invests-more-than-42-billion-Danish-kroner-in-expansion-of-manufacturing-facilities-in-Kalundborg-Denmark.html, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P3-Product-supply-updated.pdf |
| Certification | DuraTouch device received the CE mark in all European Union countries | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf |
| Regulatory approval | Wegovy pill approved in the US (Dec 2025); Alhemo approved in the US; Ozempic label updated; various approvals for Awiqli and Rybelsus in multiple regions including US, EU, Japan, and China | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.pharmamanufacturing.com/facilities/article/55360826/novo-nordisk-expands-irish-facility-with-500m-investment-to-manufacture-oral-glp-1s, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm |
| Production site | Major production sites include Denmark (Kalundborg, Hillerød, Bagsværd, Gentofte, Odense, Hjørring), USA (Clayton, North Carolina; New Hampshire), France (Chartres), China (Tianjin), Ireland (Athlone), and Brazil (Montes Claros) | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf, https://www.pharmamanufacturing.com/facilities/article/55360826/novo-nordisk-expands-irish-facility-with-500m-investment-to-manufacture-oral-glp-1s |
| Headcount | More than 69,500 employees globally as of 2025 reporting, following a workforce reduction of around 9,000 positions in 2025 | https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/novo-nordisk-annual-report-2024.pdf, https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2026/novo-nordisk-form-20-f-2025.pdf |
| Revenue | DKK 309,064 million for the full year 2025 | https://annualreport.novonordisk.com/2025/strategic-aspirations/financial-performance.html, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/nvo-20251231_d2.htm |

Independent sources: globenewswire.com, pharmamanufacturing.com, sec.gov

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)